Prevention of cervical cancer in women with HIV

Current Opinion in HIV and AIDS

Volumn 4, Issue 1, 2009, Pages 68-73

  Heard, Isabelle ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Antiviral therapy; Cervical cancer prevention; HIV infected women; Human papillomavirus

Indexed keywords

ANTIRETROVIRUS AGENT; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; COLPOSCOPY; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 67849090087     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328319bcbe     Document Type: Review

References (56)

1. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337-2344. (Pubitemid 44789536)
2. Kojic EM, Cu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 2007; 19:464-469. This review focuses on the characteristics of HPV infection and related disease in HIV and recent advances in HPV vaccines. (Pubitemid 47356603)
3. Grinsztejn B, Veloso VG, Levi JE, et al. Factors associated with increased prevalence of human papillomavirus infection in a cohort of HIV-infected Brazilian women. Int J Infect Dis 2008 Jul 14 [Epub ahead of print]. This study describes the characteristics of HPV infection in samples from 634 HIV-infected women and the factors associated with HPV infection, highlighting the high risk of infection in young women with high immunosuppression.
4. Tornesello ML, Duraturo ML, Giorgi-Rossi P, et al. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency viruspositive Italian women. J Gen Virol 2008; 89:1380-1389. This study describes the prevalence and persistence of HPV genotypes and HPV16 variants in 112 HIV-positive and 115 HIV-negative Italian women. An increased prevalence of uncommon viral genotypes and HPV16 variants is observed in HIV-positive women, highlighting the need to target a wide range of HPV types in cervical screening of high-risk women.
5. Strickler HD, Palefsky JM, Shah KV, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003; 95:1062-1071. (Pubitemid 36950110)
6. Massad LS, Seaberg EC, Wright RL, et al. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. Obstet Gynecol 2008; 111:1388-1393. This study was aimed at estimating the frequency of and trends in abnormal Pap test results among women participating in the Women's Interagency HIV Study, in the United States. This is the first study to describe the evolution of cervical abnormalities in HIV-infected women during the last decade. It shows that, although the risk of cervical lesion falls over time, the proportion of HIV-infected women with abnormal Pap tests remains above 25%, with most lesions being lowgrade. In this population of women having proper access to screening and treatment of cancer precursors, progression of cervical lesions to cancer was unlikely during 10 years of follow-up.
7. Ahdieh L, Munoz A, Vlahov D, et al. Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 2000; 151:1148-1157. (Pubitemid 30451947)
8. Lehtovirta P, Paavonen J, Heikinheimo O. Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected women. Int J STD AIDS 2008; 19:37-41. This study describes the prevalence, risk factors and prognosis of CIN among 153 HIV-infected women followed up between 1989 and 2006. Only one case of cancer of the uterine cervix was detected. Interestingly, in this study, the risk of CIN was not associated with decreased levels of CD4 cell count, duration of HIV infection, use of antiviral treatment or plasma HIV load, in contrast with most of prior studies. The conclusion of the authors is that regular follow-up by means of Pap smears is warranted in all HIV-infected women. (Pubitemid 351738841)
9. Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008; 111:1380-1387. This study describes the natural history of HPV infection and cervical disease among 400 HIV-infected women living in Cape Town, South Africa. This study shows the low rate of progression to high-grade disease in this population of women not treated with antiviral therapy. Guidelines for screening are proposed according to the low rate of progression.
10. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, et al. Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol 2006; 103:1017-1022.
11. Palefsky J. Human papillomavirus-related tumors in HIV. Curr Opin Oncol 2006; 18:463-468.
12. Massad LS, Evans CT, Minkoff H, et al. Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus. Obstet Gynecol 2004; 104:1077-1085. (Pubitemid 40458776)
13. Massad LS, Ahdieh L, Benning L, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr 2001; 27:432-442. (Pubitemid 32801071)
14. Leitao MM Jr, White P, Cracchiolo B. Cervical cancer in patients infected with the human immunodeficiency virus. Cancer 2008; 112:2683-2689. This case-control study compares the level of immunosuppression in 16 HIVinfected women with cervical cancer and 60 HIV-infected women without cervical cancer consulting in a Gynaecologic-Oncologic department. Due to lower rate of CD4 cell count among women with cancer, the authors conclude that women with cancer have a higher rate of immunosuppression. Potential bias of patients' recruitment might weaken the strength of the article. (Pubitemid 351969212)
15. Gichangi P, Bwayo J, Estambale B, et al. HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. Gynecol Oncol 2006; 100:405-411. (Pubitemid 43075277)
16. Frisch M, Biggar IJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500-1510. (Pubitemid 30757423)
17. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
18. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194. This study describes the cancer risk incidence in HIV-infected person with modest immunosuppression, before the onset of AIDS during a 12-year period spanning the introduction of HAART. The risk for invasive cancer was higher in this population than in general population. Nevertheless, incidence did not increase with declining CD4 cell count (P=0.62).
19. La Ruche G, Ramon R, Mensah-Ado I, et al. Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in Africa. Dyscer-CI Group. Cancer 1998; 82:2401-2408. (Pubitemid 28283447)
20. Carcelain G, Debre P, Autran B. Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001; 13:483-488. (Pubitemid 32728483)
21. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9:13-22. (Pubitemid 38313943)
22. Heard I, Potard V, Costagliola D. Limited impact of immunosuppresion and HAART on the incidence of cervical squamous intraepithelial lesions in HIV-positive women. Antivir Ther 2006; 11:1091-1096. (Pubitemid 44955185)
23. Soncini E, Zoncada A, Condemi V, et al. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed 2007; 78:36-40. (Pubitemid 47075721)
24. 3. J Antimicrob Chemother 2008; 61:191-194. This study shows that the incidence of cervical disease is similar in HIV-infected women with CD4 cell count above 350 cells/μl, whether or not they are on HAART, suggesting a limited impact of HAART on the progression of HPV infection to cervical disease.
25. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972. This study investigated the association between cancer risk and CD4 cell count among HIV-infected persons with AIDS. Whereas both before and after HAART was available, CD4 cell count was strongly associated with risks for Kaposi's sarcoma and non-Hodgkin's lymphoma, no association between CD4 cell count and cervical cancer was observed in either period. This observation suggests that events that permit development of malignancy from cervical lesions may not be related to immunity, at least in the time scale needed for the progression to cervical cancer.
26. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006; 19:99-105.
27. Bower M, Mazhar D, Stebbing J. Should cervical cancer be an acquired immunodeficiency syndrome-defining cancer? J Clin Oncol 2006; 24:2417-2419.
28. Martin-Hirsch PL, Paraskevaidis E, Kitchener H. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2000:CD001318.
29. Shah S, Montgomery H, Crow JC, et al. Cervical intraepithelial neoplasia treatment in human immunodeficiency virus-positive women. J Obstet Gynaecol 2008; 28:327-332. This study was aimed at investigating the effectiveness of standard surgical treatment using large loop excision of the transformation zone for CIN in 70 HIV-infected women. In only 32.8% of treatment samples, both margins were clear of CIN and a total of 55.6% patients had CIN at follow-up, despite margins being clear. This study clearly highlights the inefficacy of standard surgical treatment in the setting of HIV. (Pubitemid 351873823)
30. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007; 11:90-97. This study was aimed at describing outcomes after treatment of CIN in 170 women with HIV. Failure was more likely in women with lower CD4 cell counts and detectable HPV DNA. Most failures and recurrences were of low grade, but one adenocarcinoma was diagnosed 4.2 years after therapy for CIN 1. The authors conclude that treatment failure and recurrence are common in women with HIV but are usually of low grade. (Pubitemid 46597702)
31. Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis. Lancet Oncol 2007; 8:985-993. This meta-analysis was aimed to assess the effect of completeness of excision on the risk of posttreatment disease. It shows that incomplete excision of CIN exposes women to a substantial risk of high-grade posttreatment disease and highlights the need for close follow-up for at least 10 years. (Pubitemid 47629886)
32. Wright TC Jr, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol 1994; 55:253-258. (Pubitemid 24366635)
33. Foulot H, Heard I, Potard V, et al. Surgical management of cervical intraepithelial neoplasia in HIV-infected women. Eur J Obstet Gynecol Reprod Biol 2008 Aug 27 [Epub ahead of print]. This article describes efficacy of two excision procedures, loop excision of the transformation zone and electrosurgical conization, in obtaining complete excision of CIN in 80 HIV-infected patients. A high rate of 73% of complete excision was obtained by adapting the treatment modalities to the location of the lesion evidenced on colposcopy and to the shape of the cervix. This study highlights that appropriate surgical management leading to reduction in the rate of positive margins is needed for HIV-infected women. This may help in decreasing the risk of persistence or recurrence of lesions and thus, of cervical cancer.
34. Fruchter RG, Maiman M, Sedlis A, et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87:338-344. (Pubitemid 26075067)
35. Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:538-543. (Pubitemid 32234963)
36. Heard I, Potard V, Foulot H, et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr 2005; 39:412-418. (Pubitemid 41003785)
37. Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006; 24 (Suppl 3):S63-S70. (Pubitemid 44308671)
38. International Agency for Research on Cancer (IARC). IARC handbooks of cancer prevention, vol.10: cervix cancer screening. Lyon, France: IARC Press; 2005.
39. Anderson JR, Paramsothy P, Heilig C, et al. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006; 42:562-568. (Pubitemid 43202531)
40. Kitchener H, Nelson L, Adams J, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 2007; 121:2484-2491. The objective of this prospective multicentre study was to develop an evidence base with which clinical guidelines regarding cervical surveillance and management in HIV-infected women could be developed. The data showed that cytology was sufficient for cervical surveillance, with HPV testing being less specific with poor predictive value, which was expected in this population with high rate of HPV infection. In terms of primary screening, no additional benefit was seen from routine colposcopy. (Pubitemid 350022418)
41. Maiman M, Fruchter RG, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998; 68:233-239. (Pubitemid 28183491)
42. Maiman M, Tarricone N, Viera J, et al. Colposcopic evaluation of human immunodeficiency virus-seropositive women. Obstet Gynecol 1991; 78:84-88.
43. Fink M, Fruchter R, Maiman M, et al. The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in HIV-seropositive women. Gynecol Oncol 1994; 55:133-137. (Pubitemid 24336133)
44. IARC monographs on the evaluation of carcinogenic risks to humans. Vol.90. Human papillomaviruses. Lyon International Agency for Research on Cancer; 2007.
45. Keiser O, Martinez de Tejada B, Wunder D, et al. Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study. J Acquir Immune Defic Syndr 2006; 43:550-555. (Pubitemid 44885621)
46. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis 2007; 45:510-513. This viewpoint highlights the need for improving cervical cancer screening for HIVinfected women and analyses different reasons for inadequate screening in lowresource as well as in high-resource countries. (Pubitemid 47204472)
47. Franceschi S, Dal Maso L, Suligoi B, Rezza G. Evidence for lack of cervical cancer screening among HIV-positive women in Italy. Eur J Cancer Prev 2006; 15:554-556. (Pubitemid 44757831)
48. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907. This very elegant seminar summarizes the state-of-the-art in the setting of HPV and cervical cancer.
49. Cuzick J, Szarewski A, Mesher D, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology - results from the Hammersmith study. Int J Cancer 2008; 122:2294-2300. This study investigated the duration of protection associated with a negative primary screening HPV test in 2516 women aged 35 or more from the UK. The results indicate a longer period of protection against high-grade CIN after a negative HPV test, than that obtained after negative cytology, suggesting that HPV test alone might be the sole primary screening test in women aged 35 or more. (Pubitemid 351542334)
50. Womack SD, Chirenje ZM, Gaffikin L, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000; 85:206-210. (Pubitemid 30023069)
51. Kirby TO, Allen ME, Alvarez RD, et al. High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. J Low Genit Tract Dis 2004; 8:298-303.
52. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6:753-763.
53. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651. (Pubitemid 35340782)
54. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298:743-753. (Pubitemid 47263157)
55. Weinberg A, Song L, Handelsman E, et al. Safety and immunogenicity of a quadrivalent vaccine to prevent human papilloma virus in HIV-infected children: IMPACT P1047 [619a]. In: 15th Conference of Retrovirus and Opportunistic Infections; 2008.
56. De Vuyst H, Franceschi S. Human papillomavirus vaccines in HIV-positive men and women. Curr Opin Oncol 2007; 19:470-475. This review describes the natural history of anogenital HPV infection in HIV-infected men and women and provides recent results of both prophylactic and therapeutic HPV vaccines. The benefit of HPV vaccines in individuals with HIV is discussed. (Pubitemid 47356604)